Amager Hospital — Clinical Trial Site

18 Registered trials

5 Currently recruiting

Organisation

Amager Hospital

Location

Copenhagen S, Denmark

Identifier

ORG-100045751

Address

Italiensvej 1, 2300, Denmark

Departments

#7111
Afdelingen for hjertesygdomme CAMB Opgang 9 stuen
Cardiac Outpatient Clinic
Cardiology Department
Department of Cardiology
Department of emergency medicine
Department of Infectious Diseases
Dept Cardiology
Hjertemedicinsk Afsnit
Kardiologisk Afdeling
Kardiologisk afdeling og ambulant klinik Opgang 9, 1. sal

Clinical trials at this site (18)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Local Antibiotic Delivery for Community Acquired Pneumonia (LANDCAP 2) Pending

2024-511420-13-00 Community-acquired pneumonia 4
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
Local Antibiotic Delivery for Community Acquired Pneumonia - Pilot study (LANDCAP1) Recruiting

2024-511413-37-00 Community-acquired pneumonia 4 2025-03-03
Safety and immunogenicity of an investigational Pentavalent Meningococcal ABCYW vaccine against meningococcal disease in children, toddlers,… Ended

2023-510465-10-00 Meningococcal immunization 4 2025-03-10
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended

2022-500881-80-00 Chronic Heart Failure With Reduced Ejection Fraction 5 2021-10-29
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24
Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK) Ended

2024-515748-22-01 Myocardinal infarction 5 2018-12-01
DANHEART Ended

2024-514212-27-00 Heart failure 5